ArQule And Daiichi Sankyo Present Final Phase 2 Results For ARQ 197 C-Met Inhibitor in Non-Small Cell Lung Cancer at ASCO
Woburn, Massachusetts and Tokyo, June 7, 2010 (ots/PRNewswire) - ArQule, Inc. and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the presentation of data from a Phase 2 clinical trial at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) showing encouraging overall survival (OS) ...
plus